Jeffrey D. Bradley, MD, on NSCLC: Results of the RTOG 0617 Trial
2017 ASTRO Annual MeetingJeffrey D. Bradley, MD, of Washington University School of Medicine, discusses long-term phase III findings on standard-dose vs high-dose conformal chemoradiation therapy with or without cetuximab for stage III non–small cell lung cancer (Abstract 227).
Related Videos
James E. Bates, MD, on Pediatric Cancer Survivors: New Findings on Late Effects
James E. Bates, MD, of the University of Florida, discusses a volumetric dose-effect analysis of late cardiotoxicity, results from the Childhood Cancer Survivor Study (Abstract 4)....
Christopher R. Kelsey, MD, on DLBCL: Study Results on Consolidation Radiotherapy
Christopher R. Kelsey, MD, of Duke University Medical Center, discusses reducing the radiation dose from 30 Gy to 20 Gy for patients with diffuse large B-cell lymphoma. Phase II fi...
Marcus E. Randall, MD, on Endometrial Cancer: Results From a Gynecology Oncology Group Study
Marcus E. Randall, MD, of the University of Kentucky, discusses phase III study findings on pelvic radiation therapy vs vaginal cuff brachytherapy followed by paclitaxel/carboplati...
Shulian Wang, MD, and Benjamin Movsas, MD, on Breast Cancer: Radiation Therapy After Mastectomy
Shulian Wang, MD, of the National Cancer Center in Beijing, and Benjamin Movsas, MD, of the Henry Ford Health System, discuss study results on the use of hypofractionated radiation therapy after ma...
William A. Hall, MD, on Prostate Cancer: Results From a Study of Three Treatment Modalities
William A. Hall, MD, of the Medical College of Wisconsin, discusses trial findings on androgen deprivation and radiation alone, compared with androgen deprivation, radiotherapy, an...
